Currently the most modern M6 Cyberknife unit is in service since four years. Medical experience based on over 10.000 treated patients since 2005. Wordwide.
Learn more about the Cyberknife centre »
Meet our team
With the Cyberknife therapy tumors are well treatable if indication criteria for the radiosurgery are fulfilled.
View the treatment advantages
Ronald H., 72
Here patients share their very personal experience with the Cyberknife therapy.
View testimonials »
Johannes W, 52
Useful information and interesting facts about Cyberknife in media and science.
You are welcome to send us your patient information to have them reviewed confidentially by our E.R.C.M. experts
Report your concerns
"International Radiosurgery Oncology Consortium for Kidney" (IROCK): Radiosurgery for primary renal cell carcinoma is effective and well tolerated.
Functional outcome of AVM therapy is investigated in a randomized trial.
An ultrasound probe mounted on a robotic arm can be integrated with Cyberknife to track prostate motion.
High-dose stereotactic radiotherapy is moving towards the forefront of renal cell carcinoma treatment, with great potential in combination with...
Single fraction robotic radiosurgery for adrenal gland metastases is a safe and effective treatment option for patients who are not eligible for...
This study compares the incidence of SG after brachytherapy versus CyberKnife.
Can [18F]FET- PET overcome diagnostic uncertainties? This study investigates the usefulness of dynamic O-(2-18F-Fluoroethyl)-L-Tyrosine positron...
Publication about the impact of integrating a light-weight robotic arm carrying an ultrasound probe with the CyberKnife system.
To characterize a novel method for field-size quality assurance of a variable approximately circular aperture collimator by means of dose-area product...
Hepatocellular carcinoma: The study evaluated the long-lasting anti-tumor effects of CK combined with surgery in patients with HCC.
The “InCise™ multileaf-collimator (MLC)” is the first commercial MLC to be mounted on a robotic SRS/SBRT platform (CyberKnife).
Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma
Your direct contact to Cyberknife
+49 89 45 23 36 -0
Please send me the login credentials for the data upload.
European Radiosurgery Center Munich Max Lebsche Platz 31 D - 81377 Munich, Germany
Phone: +49-89-452336-0Fax: +49-89-452336-16
Our office is open daily:
Monday - Friday: 7.30 - 8.00 pm (CET)Saturday and Sunday 9.00 - 6.00 pm (CET)
European Radiosurgery Center MunichMax Lebsche Platz 31 D - 81377 Munich, Germany